Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients

NCT02015481 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Oculopharyngeal Muscular Dystrophy

Interventions

DRUG: Cabaletta

Sponsor

Bioblast Pharma Ltd.